Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8840928 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(9 months ago) | |
US9248195 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(9 months ago) | |
US10525052 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jul, 2023
(9 months ago) | |
US10525053 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(9 months ago) | |
US9763883 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jul, 2023
(9 months ago) | |
US9592200 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(9 months ago) | |
US9044398 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Jul, 2023
(9 months ago) | |
US8557291 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Mar, 2025
(10 months from now) | |
US7399488 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Mar, 2025
(10 months from now) | |
US8449909 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(10 months from now) | |
US7771707 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(10 months from now) | |
US8758813 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jun, 2025
(1 year, 1 month from now) | |
US10668060 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
US10004729 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
US9682075 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
US9968598 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
US10646485 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
US9737530 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
US10188644 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) |
Xtampza Er is owned by Collegium Pharm Inc.
Xtampza Er contains Oxycodone.
Xtampza Er has a total of 19 drug patents out of which 7 drug patents have expired.
Expired drug patents of Xtampza Er are:
Xtampza Er was authorised for market use on 26 April, 2016.
Xtampza Er is available in capsule, extended release;oral dosage forms.
Xtampza Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The generics of Xtampza Er are possible to be released after 02 September, 2036.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 26, 2019 |
Drugs and Companies using OXYCODONE ingredient
Market Authorisation Date: 26 April, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE;ORAL